Enoxaparin versus unfractionated heparin in primary percutaneous coronary intervention of ST-elevation acute coronary syndrome: a randomized controlled single center study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-08000269

Enrollment

Unknown

Registered

2008-12-25

Start date

2008-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease, ST-elevation acute coronary syndrome

Interventions

Group A:bolus injection of UFH 50-70U/kg before PCI

Group B:bolus injection of Enoxaparin 50U/kg before PCI

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. ST elevation ACS criteria: (1)ECG changes: New or presumably new ST-segment elevation >=0.05 MV or new left bundle branch block in at least 2 contiguous leads, or (2) Abnormal cardiac enzymes defined as elevated troponin I, T or creatine phosphokinase-MB isoenzyme (CPK-MB) level greater than double value of upper limit of normal; 2. Patients with ST elevation ACS whose symptom onset is within 12 hours of presentation and eligible to have primary PCI; 3. Willing and able to give informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients diagnosed as stable angina pectoris or Non ST elevation ACS; 2. Patients unwilling to have primary PCI; 3. History of heparin induced thrombocytopenia; 4. History of allergy to UFH, LMWH or any products from animal; 5. Unwilling or unable to give informed consent.

Design outcomes

Primary

Measure	Time frame
Liboratory index;Mortality;Days of hospitalization;	—

Secondary

Measure	Time frame
Cardiac events;Re-admission;	—

Countries

China

Contacts

Public ContactQiu Zhaohui

zhaohui_qiu@hotmail.com+86 021 62483180

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026